10-K Filing

GUARDANT HEALTH, INC. CIK: 1576280 FY 2023

Filing Information

Form Type	10-K
Accession Number	`0001576280-24-000043`
Period End Date	20231231
Filing Date	20240222
Fiscal Year	2023
Fiscal Period	FY
XBRL Instance	gh-20231231_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 73 Income Statement 75 Cash Flow Statement 141 Stockholders Equity 40 Comprehensive Income 21

Balance Sheet 73 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in usd per share)	`PreferredStockParOrStatedValuePerShare`	-	USD	Point-in-time
Preferred stock, par value (in usd per share)	`PreferredStockParOrStatedValuePerShare`	-	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$492.20M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.13B	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$141.65M	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Short-term marketable debt securities	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$35.10M	USD	Point-in-time
Short-term marketable debt securities	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$869.58M	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$97.26M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$88.78M	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Inventory, net	`InventoryNet`	$51.60M	USD	Point-in-time
Inventory, net	`InventoryNet`	$61.95M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	121.63M	shares	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$31.51M	USD	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$27.74M	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	102.62M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$1.19B	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	102.62M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	121.63M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$1.35B	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$145.10M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$167.92M	USD	Point-in-time
Right-of-use assets, net	`OperatingLeaseRightOfUseAsset`	$174.00M	USD	Point-in-time
Right-of-use assets, net	`OperatingLeaseRightOfUseAsset`	$157.62M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$8.98M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$11.73M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$61.45M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$124.33M	USD	Point-in-time
Total Assets	`Assets`	$1.79B	USD	Point-in-time
Total Assets	`Assets`	$1.61B	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$187.95M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$175.82M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$17.96M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$17.40M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$205.92M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$193.22M	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$1.14B	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$1.14B	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$210.01M	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$185.85M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$9.18M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$96.01M	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.55B	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.63B	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022	`PreferredStockValueOutstanding`	-	USD	Point-in-time
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022	`PreferredStockValueOutstanding`	-	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, 2023 and 2022; 121,629,861 and 102,619,383 shares issued and outstanding as of December 31, 2023 and 2022, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, 2023 and 2022; 121,629,861 and 102,619,383 shares issued and outstanding as of December 31, 2023 and 2022, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$2.30B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.74B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-3.67M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-19.52M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-2.14B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.66B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$60.18M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.30B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$158.68M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$645.00M	USD	Point-in-time
Total Liabilities and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$1.61B	USD	Point-in-time
Total Liabilities and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$1.79B	USD	Point-in-time

Income Statement 75 line items

Line Item	Tag	Value	Unit	Period
Precision oncology testing	`RevenueFromPrecisionOncologyTesting`	$304.31M	USD	Annual
Precision oncology testing	`RevenueFromPrecisionOncologyTesting`	$392.05M	USD	Annual
Precision oncology testing	`RevenueFromPrecisionOncologyTesting`	$514.25M	USD	Annual
Development services and other	`RevenueFromDevelopmentServices`	$49.70M	USD	Annual
Development services and other	`RevenueFromDevelopmentServices`	$69.34M	USD	Annual
Development services and other	`RevenueFromDevelopmentServices`	$57.49M	USD	Annual
Total revenue	`Revenues`	$373.65M	USD	Annual
Total revenue	`Revenues`	$449.54M	USD	Annual
Total revenue	`Revenues`	$563.95M	USD	Annual
Cost of precision oncology testing	`CostsOfPrecisionOncologyTesting`	$205.53M	USD	Annual
Cost of precision oncology testing	`CostsOfPrecisionOncologyTesting`	$110.40M	USD	Annual
Cost of precision oncology testing	`CostsOfPrecisionOncologyTesting`	$148.20M	USD	Annual
Cost of development services and other	`CostOfDevelopmentServices`	$8.13M	USD	Annual
Cost of development services and other	`CostOfDevelopmentServices`	$21.52M	USD	Annual
Cost of development services and other	`CostOfDevelopmentServices`	$12.52M	USD	Annual
Research and development expense	`ResearchAndDevelopmentExpense`	$367.19M	USD	Annual
Research and development expense	`ResearchAndDevelopmentExpense`	$263.22M	USD	Annual
Research and development expense	`ResearchAndDevelopmentExpense`	$373.81M	USD	Annual
Sales and marketing expense	`SellingAndMarketingExpense`	$295.23M	USD	Annual
Sales and marketing expense	`SellingAndMarketingExpense`	$299.83M	USD	Annual
Sales and marketing expense	`SellingAndMarketingExpense`	$191.88M	USD	Annual
General and administrative expense	`GeneralAndAdministrativeExpense`	$163.96M	USD	Annual
General and administrative expense	`GeneralAndAdministrativeExpense`	$155.80M	USD	Annual
General and administrative expense	`GeneralAndAdministrativeExpense`	$206.64M	USD	Annual
Other operating expense	`OtherCostAndExpenseOperating`	-	USD	Annual
Other operating expense	`OtherCostAndExpenseOperating`	$83.40M	USD	Annual
Other operating expense	`OtherCostAndExpenseOperating`	-	USD	Annual
Total costs and operating expenses	`CostsAndExpenses`	$993.92M	USD	Annual
Total costs and operating expenses	`CostsAndExpenses`	$784.65M	USD	Annual
Total costs and operating expenses	`CostsAndExpenses`	$1.13B	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-564.73M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-544.38M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-411.00M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$3.93M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$6.07M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$35.37M	USD	Annual
Interest expense	`InterestExpense`	$2.58M	USD	Annual
Interest expense	`InterestExpense`	$2.58M	USD	Annual
Interest expense	`InterestExpense`	$2.58M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$25.18M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-12.78M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$53.17M	USD	Annual
Fair value adjustments of noncontrolling interest liability	`FairValueOptionChangesInFairValueGainLoss1`	$-99.78M	USD	Annual
Fair value adjustments of noncontrolling interest liability	`FairValueOptionChangesInFairValueGainLoss1`	-	USD	Annual
Fair value adjustments of noncontrolling interest liability	`FairValueOptionChangesInFairValueGainLoss1`	-	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-384.47M	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-653.45M	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-478.76M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$300.00K	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$685.00K	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$1.14M	USD	Annual
Net loss	`ProfitLoss`	$-479.45M	USD	Annual
Net loss	`ProfitLoss`	$-384.77M	USD	Annual
Net loss	`ProfitLoss`	$-654.59M	USD	Annual
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	-	USD	Annual
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	-	USD	Annual
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$20.90M	USD	Annual
Net loss attributable to Guardant Health, Inc. common stockholders - basic	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-479.45M	USD	Annual
Net loss attributable to Guardant Health, Inc. common stockholders - basic	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-405.67M	USD	Annual
Net loss attributable to Guardant Health, Inc. common stockholders - basic	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-654.59M	USD	Annual
Net loss attributable to Guardant Health, Inc. common stockholders - diluted	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-405.67M	USD	Annual
Net loss attributable to Guardant Health, Inc. common stockholders - diluted	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-479.45M	USD	Annual
Net loss attributable to Guardant Health, Inc. common stockholders - diluted	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-654.59M	USD	Annual
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-6.41	USD	Annual
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-4.00	USD	Annual
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-4.28	USD	Annual
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-4.28	USD	Annual
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-6.41	USD	Annual
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-4.00	USD	Annual
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	102.18M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	101.31M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	111.99M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	101.31M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	111.99M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	102.18M	shares	Annual

Cash Flow Statement 141 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-384.77M	USD	Annual
Net loss	`NetIncomeLoss`	$-479.45M	USD	Annual
Net loss	`NetIncomeLoss`	$-654.59M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$42.88M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$22.27M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$35.96M	USD	Annual
Operating lease costs	`NonCashOperatingLeaseCosts`	$24.66M	USD	Annual
Operating lease costs	`NonCashOperatingLeaseCosts`	$29.70M	USD	Annual
Operating lease costs	`NonCashOperatingLeaseCosts`	$28.59M	USD	Annual
Contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$4.30M	USD	Annual
Contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$2.38M	USD	Annual
Contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$110.00K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$94.69M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$90.76M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$151.45M	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$2.56M	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$2.58M	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$2.57M	USD	Annual
Amortization of (discount) premium on marketable debt securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-4.59M	USD	Annual
Amortization of (discount) premium on marketable debt securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-12.85M	USD	Annual
Amortization of (discount) premium on marketable debt securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$13.55M	USD	Annual
Unrealized (gains) losses on marketable equity securities	`EquitySecuritiesFvNiUnrealizedGainLoss`	-	USD	Annual
Unrealized (gains) losses on marketable equity securities	`EquitySecuritiesFvNiUnrealizedGainLoss`	$79.71M	USD	Annual
Unrealized (gains) losses on marketable equity securities	`EquitySecuritiesFvNiUnrealizedGainLoss`	$-7.79M	USD	Annual
Impairment of non-marketable equity securities and other related assets	`OtherAssetImpairmentCharges`	$29.05M	USD	Annual
Impairment of non-marketable equity securities and other related assets	`OtherAssetImpairmentCharges`	-	USD	Annual
Impairment of non-marketable equity securities and other related assets	`OtherAssetImpairmentCharges`	$5.26M	USD	Annual
Fair value adjustments of noncontrolling interest liability	`FairValueAdjustmentsOfNoncontrollingInterestLiability`	$-99.78M	USD	Annual
Fair value adjustments of noncontrolling interest liability	`FairValueAdjustmentsOfNoncontrollingInterestLiability`	-	USD	Annual
Fair value adjustments of noncontrolling interest liability	`FairValueAdjustmentsOfNoncontrollingInterestLiability`	-	USD	Annual
Other	`OtherNoncashIncomeExpense`	$-47.00K	USD	Annual
Other	`OtherNoncashIncomeExpense`	$-21.00K	USD	Annual
Other	`OtherNoncashIncomeExpense`	$1.18M	USD	Annual
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$44.35M	USD	Annual
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-8.38M	USD	Annual
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-375.00K	USD	Annual
Inventory, net	`IncreaseDecreaseInInventories`	$20.93M	USD	Annual
Inventory, net	`IncreaseDecreaseInInventories`	$10.35M	USD	Annual
Inventory, net	`IncreaseDecreaseInInventories`	$7.96M	USD	Annual
Prepaid expenses and other current assets, net	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-20.44M	USD	Annual
Prepaid expenses and other current assets, net	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$4.33M	USD	Annual
Prepaid expenses and other current assets, net	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$35.75M	USD	Annual
Other assets, net	`IncreaseDecreaseInOtherOperatingAssets`	$-11.70M	USD	Annual
Other assets, net	`IncreaseDecreaseInOtherOperatingAssets`	$4.18M	USD	Annual
Other assets, net	`IncreaseDecreaseInOtherOperatingAssets`	$-1.30M	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities`	$34.80M	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities`	$60.33M	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities`	$88.59M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$14.21M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-20.23M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-31.48M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$9.87M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$2.78M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$1.73M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-309.46M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-324.98M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-209.02M	USD	Annual
Purchase of marketable debt securities	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$900.81M	USD	Annual
Purchase of marketable debt securities	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$629.90M	USD	Annual
Purchase of marketable debt securities	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$303.76M	USD	Annual
Maturity of marketable debt securities	`ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities`	$952.11M	USD	Annual
Maturity of marketable debt securities	`ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities`	$555.00M	USD	Annual
Maturity of marketable debt securities	`ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities`	$1.49B	USD	Annual
Purchase of non-marketable equity securities and other related assets	`PaymentsToAcquireEquitySecuritiesFvNi`	$5.59M	USD	Annual
Purchase of non-marketable equity securities and other related assets	`PaymentsToAcquireEquitySecuritiesFvNi`	$23.97M	USD	Annual
Purchase of non-marketable equity securities and other related assets	`PaymentsToAcquireEquitySecuritiesFvNi`	$39.42M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$77.46M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$75.03M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$20.49M	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-1.53M	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	-	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	-	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-63.16M	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$149.82M	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$840.25M	USD	Annual
Proceeds from issuance of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$10.15M	USD	Annual
Proceeds from issuance of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$9.32M	USD	Annual
Proceeds from issuance of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$9.75M	USD	Annual
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$2.62M	USD	Annual
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$405.00K	USD	Annual
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$8.11M	USD	Annual
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$83.76M	USD	Annual
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$11.20M	USD	Annual
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$7.88M	USD	Annual
Proceeds from equity offerings	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from equity offerings	`ProceedsFromIssuanceOfCommonStock`	$381.40M	USD	Point-in-time
Proceeds from equity offerings	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from equity offerings	`ProceedsFromIssuanceOfCommonStock`	$493.12M	USD	Annual
Proceeds from equity offerings	`ProceedsFromIssuanceOfCommonStock`	$90.60M	USD	Point-in-time
Payment of equity offering costs	`PaymentsOfStockIssuanceCosts`	$21.13M	USD	Annual
Payment of equity offering costs	`PaymentsOfStockIssuanceCosts`	-	USD	Annual
Payment of equity offering costs	`PaymentsOfStockIssuanceCosts`	-	USD	Annual
Joint Venture Acquisition	`PaymentsForJointVentureAcquisitionFinancingActivities`	$177.78M	USD	Annual
Joint Venture Acquisition	`PaymentsForJointVentureAcquisitionFinancingActivities`	-	USD	Annual
Joint Venture Acquisition	`PaymentsForJointVentureAcquisitionFinancingActivities`	-	USD	Annual
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	`NoncashTenderOfferIssued`	-	USD	Annual
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	`NoncashTenderOfferIssued`	-	USD	Annual
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	`NoncashTenderOfferIssued`	$-14.23M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-1.14M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$6.03M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-930.00K	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$477.38M	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-189.09M	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-66.82M	USD	Annual
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$-1.69M	USD	Annual
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$-1.60M	USD	Annual
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$-911.00K	USD	Annual
Net increase (decrease) in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$991.74M	USD	Annual
Net increase (decrease) in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-340.69M	USD	Annual
Net increase (decrease) in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-350.34M	USD	Annual
Cash, cash equivalents and restricted cash Beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$141.95M	USD	Point-in-time
Cash, cash equivalents and restricted cash Beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash, cash equivalents and restricted cash Beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$492.29M	USD	Point-in-time
Cash, cash equivalents and restricted cash Beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.13B	USD	Point-in-time
Cash, cash equivalents and restricted cash End of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$141.95M	USD	Point-in-time
Cash, cash equivalents and restricted cash End of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash, cash equivalents and restricted cash End of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$492.29M	USD	Point-in-time
Cash, cash equivalents and restricted cash End of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.13B	USD	Point-in-time
Cash paid for income taxes	`IncomeTaxesPaidNet`	$1.97M	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$1.33M	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$393.00K	USD	Annual
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$4.07M	USD	Annual
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$5.01M	USD	Annual
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$171.38M	USD	Annual
Purchase of property and equipment included in accounts payable and accrued liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$5.28M	USD	Annual
Purchase of property and equipment included in accounts payable and accrued liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$8.29M	USD	Annual
Purchase of property and equipment included in accounts payable and accrued liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$8.89M	USD	Annual
Reclassification of redeemable noncontrolling interest to noncontrolling interest liability	`InvestmentsPayable`	$78.00M	USD	Point-in-time
Reclassification of redeemable noncontrolling interest to noncontrolling interest liability	`InvestmentsPayable`	$78.00M	USD	Point-in-time
Reclassification of redeemable noncontrolling interest to noncontrolling interest liability	`InvestmentsPayable`	-	USD	Point-in-time
Reclassification of redeemable noncontrolling interest to noncontrolling interest liability	`InvestmentsPayable`	-	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$492.20M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.13B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$141.65M	USD	Point-in-time
Restricted cash included in other assets, net	`RestrictedCashNoncurrent`	$86.00K	USD	Point-in-time
Restricted cash included in other assets, net	`RestrictedCashNoncurrent`	$150.00K	USD	Point-in-time
Restricted cash included in other assets, net	`RestrictedCashNoncurrent`	$301.00K	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$141.95M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$492.29M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.13B	USD	Point-in-time

Stockholders Equity 40 line items

Line Item	Tag	Value	Unit	Period
Issuance of common stock upon follow-on public offering, net of offering costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$21.13M	USD	Annual
Issuance of common stock upon follow-on public offering, net of offering costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$21.10M	USD	Point-in-time
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-20.90M	USD	Annual
Beginning balance	`StockholdersEquity`	$60.18M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.30B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$158.68M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$645.00M	USD	Point-in-time
Issuance of common stock upon follow-on offering, net of offering costs (in shares)	`StockIssuedDuringPeriodSharesNewIssues`	14.38M	shares	Point-in-time
Issuance of common stock upon follow-on offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$381.37M	USD	Annual
Issuance of common stock upon registered direct offering (in shares)	`StockIssuedDuringPeriodSharesRegisteredDirectOffering`	3.39M	shares	Point-in-time
Issuance of common stock upon registered direct offering	`StockIssuedDuringPeriodValueRegisteredDirectOffering`	$90.62M	USD	Annual
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	228,311.00	shares	Annual
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	693,074.00	shares	Annual
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	51,124.00	shares	Annual
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.62M	USD	Annual
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$8.11M	USD	Annual
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$405.00K	USD	Annual
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$52.00K	USD	Annual
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$8.00K	USD	Annual
Issuance of common stock under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$9.32M	USD	Annual
Issuance of common stock under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$10.15M	USD	Annual
Issuance of common stock under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$9.75M	USD	Annual
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$7.88M	USD	Annual
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$83.76M	USD	Annual
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$11.20M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$90.76M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$94.69M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$151.45M	USD	Annual
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-20.90M	USD	Annual
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	`AdjustmentsToAdditionalPaidInCapitalTenderOfferIssued`	$14.23M	USD	Annual
Other comprehensive (loss) income, net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-14.76M	USD	Annual
Other comprehensive (loss) income, net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$15.85M	USD	Annual
Other comprehensive (loss) income, net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-7.46M	USD	Annual
Net loss	`NetIncomeLoss`	$-384.77M	USD	Annual
Net loss	`NetIncomeLoss`	$-479.45M	USD	Annual
Net loss	`NetIncomeLoss`	$-654.59M	USD	Annual
Ending balance	`StockholdersEquity`	$60.18M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.30B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$158.68M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$645.00M	USD	Point-in-time

Comprehensive Income 21 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-479.45M	USD	Annual
Net loss	`ProfitLoss`	$-384.77M	USD	Annual
Net loss	`ProfitLoss`	$-654.59M	USD	Annual
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-5.77M	USD	Annual
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-13.16M	USD	Annual
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$16.76M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-1.69M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-911.00K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-1.60M	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-14.76M	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$15.85M	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-7.46M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-669.35M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-463.60M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-392.23M	USD	Annual
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	-	USD	Annual
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	-	USD	Annual
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$20.90M	USD	Annual
Comprehensive loss attributable to Guardant Health, Inc. common stockholders	`ComprehensiveIncomeNetOfTax`	$-669.35M	USD	Annual
Comprehensive loss attributable to Guardant Health, Inc. common stockholders	`ComprehensiveIncomeNetOfTax`	$-413.13M	USD	Annual
Comprehensive loss attributable to Guardant Health, Inc. common stockholders	`ComprehensiveIncomeNetOfTax`	$-463.60M	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.